TSCM DNDN
|
Dendreon & Deceit: Jim Cramer, Pequot
Capital -07/19/09 at
12:02 PM CDTby Mark
Mitchell
“SELL! SELL! SELL!” shouted Jim
Cramer on March 28, 2007. The CNBC “journalist” assured
his viewers that the FDA advisory panel would vote that
Dendreon’s treatment for prostate cancer was neither safe nor
effective (notwithstanding the fact that the FDA had given the
treatment “priority review” status because Pro...
|
|
DNDN
|
Profiting From Demise: Steve Cohen, Millennium Management, and
Dendreon -07/09/09 at
11:55 AM CDTby Mark
Mitchell
D.H. Blair, the Mafia-affiliated brokerage
founded by Lindsay Rosenwald’s father-in-law (the so-called
“king of stock fraud”) and managed for some time by
Rosenwald and Michael Milken’s former national sales manager,
received much of its finance from the family of a man named Zev
Wolfson. Mr. Wolfson was also closely involved with...
|
|
DNDN
|
The Madoff Exemption and the Story of Dendreon (Chapter
2) -06/30/09 at 5:32 PM
CDTby Mark Mitchell
In January 2007, some 15 months after
CNBC’s Jim Cramer announced that the FDA had rejected
Provenge (even though the agency had not yet reviewed Provenge),
the FDA assigned “priority review status” to
Dendreon’s application to have the drug approved. Such status
is typically granted to drugs whose trials suggest that they can
sign...
|
|
GE TSCM DNDN
|
Michael Milken, 60,000 Deaths, and the Story of Dendreon, Chapter
1 -06/24/09 at 1:38 PM
CDTby Mark Mitchell
This story, like too many others, begins with
Jim Cramer, the CNBC personality, making “a mistake.”
On September 26, 2005, Cramer announced to his television
audience the sad news (punctuated by funny sound effects – a
clown horn, a crashing airplane) that Provenge, an experimental
treatment for prostate cancer, had flopped. Thousan...
|
|